Shots:
- Reflow Medical has reported the DEEPER CORONARY study results evaluating the short-term safety of the coronary Spur Elute Sirolimus-Eluting Retrievable Stent System for coronary ISR at EuroPCR 2026
- 6mos. results showed 100% freedom from MACE & all-cause mortality in nine treated pts, while all patients demonstrated improved CCS angina class with a median improvement of three classes
- Spur Elute Stent System is the first retrievable self-expanding stent with drug-coated expandable spikes & an integrated balloon delivering sirolimus-based Retrievable Scaffold Therapy (RST) to enhance drug uptake, support the artery, maximize luminal diameter, & reduce restenosis without leaving a permanent implant
Ref: Businesswire | Image: Reflow Medical | Press Release
Related News: Reflow Medical’s Spur Peripheral Retrievable Stent System Receives the US FDA’s De Novo Clearance for BTK-CLTI Treatment
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
